UA98508C2 - Иммуномодуляторное производное дипептида для лечения рака легких - Google Patents

Иммуномодуляторное производное дипептида для лечения рака легких

Info

Publication number
UA98508C2
UA98508C2 UAA201003197A UAA201003197A UA98508C2 UA 98508 C2 UA98508 C2 UA 98508C2 UA A201003197 A UAA201003197 A UA A201003197A UA A201003197 A UAA201003197 A UA A201003197A UA 98508 C2 UA98508 C2 UA 98508C2
Authority
UA
Ukraine
Prior art keywords
lung cancer
immunomodulatory
treatment
dipeptide derivative
dipeptide
Prior art date
Application number
UAA201003197A
Other languages
English (en)
Ukrainian (uk)
Inventor
Синтия В. Татхилл
Original Assignee
Сайклон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сайклон Фармасьютикалз, Инк. filed Critical Сайклон Фармасьютикалз, Инк.
Publication of UA98508C2 publication Critical patent/UA98508C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Изобретение касается соединения иммуномодулятора формулы А или ее фармацевтически приемлемой соли,где n равняется 1 или 2, R является водородом, Cацилом или Салкилом, а X является L-триптофаном или D-триптофаном, для применения в лечении рака легких.
UAA201003197A 2007-08-23 2008-08-21 Иммуномодуляторное производное дипептида для лечения рака легких UA98508C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95753007P 2007-08-23 2007-08-23
PCT/US2008/009932 WO2009025830A1 (en) 2007-08-23 2008-08-21 Treatment of lung cancer

Publications (1)

Publication Number Publication Date
UA98508C2 true UA98508C2 (ru) 2012-05-25

Family

ID=40378469

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201003197A UA98508C2 (ru) 2007-08-23 2008-08-21 Иммуномодуляторное производное дипептида для лечения рака легких

Country Status (14)

Country Link
US (1) US20110189305A1 (ru)
EP (1) EP2192835A4 (ru)
JP (1) JP2010536854A (ru)
KR (1) KR20100063078A (ru)
CN (1) CN101842009A (ru)
AU (1) AU2008289522A1 (ru)
BR (1) BRPI0815772A2 (ru)
CA (1) CA2697261A1 (ru)
EA (1) EA201070295A1 (ru)
MX (1) MX2010002046A (ru)
NZ (1) NZ584065A (ru)
UA (1) UA98508C2 (ru)
WO (1) WO2009025830A1 (ru)
ZA (1) ZA201001876B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA96980C2 (ru) 2007-02-13 2011-12-26 Сайклон Фармасютикалс, Инк. Способ уменьшения степени ухудшения состояния, поражения или повреждения слизистой оболочки
RU2519738C2 (ru) * 2011-12-12 2014-06-20 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения и социального развития Российской Федерации Способ лечения рака легкого

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902790A (en) * 1995-10-03 1999-05-11 Cytran, Inc. Pharmaceutical angiostatic dipeptide compositions and method of use thereof
US5744452A (en) * 1995-11-28 1998-04-28 Edward T. Wei γ-L-glutamyl containing immunomodulator compounds and methods therewith
US5916878A (en) * 1995-11-28 1999-06-29 Edward T. Wei γ-glutamyl and β-aspartyl containing immunomodulator compounds and methods therewith
RU2141483C1 (ru) * 1997-07-04 1999-11-20 Небольсин Владимир Евгеньевич Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция
RU2229892C2 (ru) * 2001-06-08 2004-06-10 Государственное учреждение "Санкт-Петербургский научно-исследовательский институт фтизиопульмонологии" Способ лечения туберкулеза легких

Also Published As

Publication number Publication date
CA2697261A1 (en) 2009-02-26
ZA201001876B (en) 2010-11-24
US20110189305A1 (en) 2011-08-04
KR20100063078A (ko) 2010-06-10
EP2192835A1 (en) 2010-06-09
CN101842009A (zh) 2010-09-22
NZ584065A (en) 2012-03-30
JP2010536854A (ja) 2010-12-02
MX2010002046A (es) 2010-05-03
BRPI0815772A2 (pt) 2014-09-30
EA201070295A1 (ru) 2010-10-29
EP2192835A4 (en) 2010-11-10
AU2008289522A1 (en) 2009-02-26
WO2009025830A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
JO2848B1 (en) Organic compounds
UA98141C2 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
MY147832A (en) Compounds for enzyme inhibition
TW200738725A (en) Unsaturated mTOR inhibitors
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
EA201300860A1 (ru) Кристаллические трипептидные ингибиторы эпоксикетон-протеазы
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
HK1120441A1 (en) Drugs for treatment of ovarian cancer
MX2009009574A (es) Tratamiento de melanoma.
WO2012078757A3 (en) Combination for breast cancer therapy with hsp90 inhibitory compounds
MX2013003060A (es) Terapia de combinacion para tratar infeccion por hcv.
TW200700071A (en) Novel use
EA200900691A1 (ru) Применение ингибиторов iap для лечения острого миелоидного лейкоза
UA100702C2 (ru) Комбинационная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства - гемцитабина
TNSN07294A1 (en) Treatment of metastasized tumors
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
WO2010121675A3 (en) Thiazolyl-benzimidazoles
JO3145B1 (ar) مركبات مفيدة لتثبيط chk1
MX348758B (es) Derivados de sanglifehrina y metodos para su produccion.
MX2011009804A (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo.
UA98508C2 (ru) Иммуномодуляторное производное дипептида для лечения рака легких
MX2012000203A (es) Procedimientos de uso del factor liberador de corticotropina para el tratamiento de cancer.
WO2007123847A3 (en) Treatment of melanoma